Wei Wei, PhD

Assistant Professor of Medicine (Medical Oncology)

DownloadHi-Res Photo

Appointments

Medical Oncology and Hematology

Primary

Additional Titles

Interim Director of Biostatistics Shared Resource, Yale Cancer Center

Contact Info

wei.wei@yale.edu

About

Titles

Assistant Professor of Medicine (Medical Oncology)

Interim Director of Biostatistics Shared Resource, Yale Cancer Center

Biography

Wei Wei is an Associate Professor at Yale School of Medicine and Director of the Biostatistics Shared Resource at Yale Cancer Center. Dr. Wei's research area focuses on development of early phase clinical trial designs, with particular interest in cancer targeted and immunotherapeutic agents.

Last Updated on January 07, 2026.

Appointments

Medical Oncology and Hematology
Assistant Professor
Primary

Internal Medicine
Medical Oncology and Hematology
Yale Cancer Center

Education & Training

PhD: Medical University of South Carolina, Biostatistics (2016)

- Download CV

Research

Overview

Public Health Interests

Clinical Trials; Cancer; Biomarkers

ORCID
0000-0003-1263-5620

Research at a Glance

Yale Co-Authors

Frequent collaborators of Wei Wei's published research.

Harriet Kluger, MD
View Full Profile
View 17 Common Publications
David Rimm, MD, PhD
View Full Profile
View 12 Common Publications
Amit Mahajan, MD
View Full Profile
View 6 Common Publications
Daniel Zelterman, PhD
View Full Profile
View 6 Common Publications
Jan Philipp Bewersdorf, MD, FACP
View Full Profile
View 6 Common Publications
Michael Kane, PhD, MA, MS
View Full Profile
View 6 Common Publications

Publications

2026

Bayesian randomized basket trial design: a case study from the ultra-rare invasive mold infections
Liu Y, Roychoudhury S, Wei W. Bayesian randomized basket trial design: a case study from the ultra-rare invasive mold infections. Biometrics 2026, 82: ujag001. PMID: 41608839, DOI: 10.1093/biomtc/ujag001.
Peer-Reviewed Original Research
MeSH Keywords

2025

Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas
Cheung J, Hunt B, Wahed S, Cheng E, Connolly K, Venkatesan S, Loza J, Bansal I, Fagerberg E, Kessler E, Riffard C, Buck J, Attanasio J, Borr E, Wei W, William I, Fitzgerald B, Joshi N. Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer Cell 2025, 43: 2311-2326.e4. PMID: 41043437, PMCID: PMC12693725, DOI: 10.1016/j.ccell.2025.09.005.
Peer-Reviewed Original Research
Concepts
The Maximum Negative Hypergeometric Distribution
Yu C, Prishwalko K, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. The Maximum Negative Hypergeometric Distribution. Journal Of Statistical Theory And Practice 2025, 19: 88. DOI: 10.1007/s42519-025-00502-x.
Peer-Reviewed Original Research
Concepts
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
. Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. European Journal Of Cancer 2025, 227: 115641. PMID: 40795524, DOI: 10.1016/j.ejca.2025.115641.
Peer-Reviewed Original Research
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2025 Jul;212(2):299-308. doi: 10.1007/s10549-025-07725-3. Epub 2025 May 15. PMID: 40369346.
Peer-Reviewed Original Research
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
Ajjawi I, Rios A, Wei W, Park T, Lustberg M. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Research And Treatment 2025, 212: 299-308. PMID: 40369346, DOI: 10.1007/s10549-025-07725-3.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers (Basel). 2025 May 6;17(9):1579. doi: 10.3390/cancers17091579. PMID: 40361505; PMCID: PMC12072055.
Peer-Reviewed Original Research
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
Ajjawi I, Rios A, Wei W, Park T, Lustberg M. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers 2025, 17: 1579. PMID: 40361505, PMCID: PMC12072055, DOI: 10.3390/cancers17091579.
Peer-Reviewed Original Research
Concepts
Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Bhatia A, Mehra R, Bauman J, Khan S, Wei W, Neumeister V, Sandoval‐Schaefer T, Alpaugh R, Lango M, Rimm D, Ridge J, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck 2025, 47: 2373-2382. PMID: 40166973, DOI: 10.1002/hed.28152.
Peer-Reviewed Original Research
This study investigates the efficacy of adding erlotinib to chemotherapy and cetuximab for head and neck cancer, showing improved response rates, highlighting potential for dual EGFR targeting in treatment.
Full Summary
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.
Peer-Reviewed Original Research
Concepts

See All Publications

Academic Achievements & Community Involvement

Activities

activity
Leukemia & Lymphoma Society
2025 - PresentPeer Review Groups and Grant Study SectionsGrant Reviewer
activity
Design and Implementation of Clinical Trials
11/17/2025 - 11/21/2025LectureWinn-AACR Design and Implementation of Clinical Trials Workshop
Details
Albuquerque, NM, United StatesSponsored by American Association for Cancer Research
Collaborators
Yu ShyrVanderbilt University Medical Center

Teaching & Mentoring

Mentoring

Jinping Liang
Graduate student
2025 - Present
Michelle Song
Graduate student
2025 - Present
Yunhe Liu
Graduate student at YSPH
2022 - 2024
Yunxuan Zhang
Graduate student at YSPH
2022 - 2023

Willing and Available to Mentor
- Faculty
- Students
- Residents
- Postdoctoral Researchers
- Clinical Fellows
- Clinicians

News

Get In Touch

Contacts

wei.wei@yale.edu

Appointments

Additional Titles

Contact Info

Titles

Biography

Appointments

Medical Oncology and Hematology

Other Departments & Organizations

Education & Training

Overview

Public Health Interests

ORCID

Research at a Glance

Yale Co-Authors

Harriet Kluger, MD

David Rimm, MD, PhD

Amit Mahajan, MD

Daniel Zelterman, PhD

Jan Philipp Bewersdorf, MD, FACP

Michael Kane, PhD, MA, MS

Publications

2026

2025

Activities

Leukemia & Lymphoma Society

Design and Implementation of Clinical Trials

Mentoring

Jinping Liang

Michelle Song

Yunhe Liu

Yunxuan Zhang

Willing and Available to Mentor

News

Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma

Discoveries & Impact (August 2022)

Contacts